This is a prospective, double-blind, sham-controlled, randomized clinical trial . This study aims to assess the efficacy, safety, tolerability, and the optimal dose of the Mi-Helper transnasal cooling device for acute treatment of migraine in an at home setting. Adults aged 18 years to 65 years old with a diagnosis of episodic migraine (with or without aura) for at least one year (self-reported) will be recruited for this study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
172
The Mi-Helper device is a non-invasive, drug-free, novel therapy that uses a patented process of dry air flow across the nasal turbinates to induce a phase change (evaporation) that extracts energy (thermodynamics) causing local cooling which modulates nerves associated with pain and other symptoms of migraine. The device delivers a controlled pressure and flow of dry room temperature air along with a nebulized saline mist for added comfort and evaporative efficiency.
ObvioHealth
New York, New York, United States
Pain relief at 2 hours post treatment
From severe or moderate to mild or no pain, or from mild to no pain; based on the traditional 4-point VRS scale
Time frame: 2 hours
Safety of the Mi-Helper device
Measured by incidence of adverse events
Time frame: 24 hours
Tolerability of the Mi-Helper device
Based on percent of participants who fail to complete the full treatment session
Time frame: 15 minutes
Pain relief immediately post treatment
From severe or moderate to mild or no pain, or from mild to no pain; based on the traditional 4-point VRS scale
Time frame: 0 minutes
Pain relief at 24 hours post treatment
From severe or moderate to mild or no pain, or from mild to no pain; based on the traditional 4-point VRS scale
Time frame: 24 hours
Pain freedom immediately post treatment
A reduction of mild, moderate or severe pain at baseline to no pain.
Time frame: 0 minutes
Pain freedom at 2 hours post treatment
A reduction of mild, moderate or severe pain at baseline to no pain.
Time frame: 2 hours
Pain freedom at 24 hours post treatment
A reduction of mild, moderate or severe pain at baseline to no pain.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 24 hours
Relief from most bothersome symptom (MBS) immediately post treatment
From severe or moderate to mild or none, or from mild to none; based on the traditional 4-point VRS scale
Time frame: 0 minutes
Relief from MBS at 2 hours post treatment
From severe or moderate to mild or none, or from mild to none; based on the traditional 4-point VRS scale
Time frame: 2 hours
Relief from MBS at 24 hours post treatment
From severe or moderate to mild or none, or from mild to none; based on the traditional 4-point VRS scale
Time frame: 24 hours
Freedom from MBS immediately post treatment
A reduction of mild, moderate or severe pain at baseline to none.
Time frame: 0 minutes
Freedom from MBS at 2 hours post treatment
A reduction of mild, moderate or severe pain at baseline to none.
Time frame: 2 hours
Freedom from MBS at 24 hours post treatment
A reduction of mild, moderate or severe pain at baseline to none.
Time frame: 24 hours